Advertisement

Topics

Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia

20:00 EDT 13 Jun 2018 | BioSpace

Days after the U.S. Food and Drug Administration provided an expedited path forward for Sage Therapeutics’ depression treatment SAGE-217, the company snagged a deal worth $575 million.

Original Article: Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia

NEXT ARTICLE

More From BioPortfolio on "Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Psychiatry
Psychiatry is the study of mental disorders and their diagnosis, management and prevention.  Conditions include schizophrenia, severe depression and panic disorders among others. There are pharmaceutical treatments as well as other therapies to help...